Effect of a protease‐activated receptor‐2 antagonist (GB88) on inflammation‐related loss of alveolar bone in periodontal disease

Abstract

AbstractBackground and ObjectiveProtease‐activated receptor‐2 (PAR2), a pro‐inflammatory G‐protein coupled receptor, has been associated with pathogenesis of periodontitis and the resulting bone loss caused by oral pathogens, including the keystone pathogen Porphyromonas gingivalis (P. gingivalis). We hypothesised that administration of a PAR2 antagonist, GB88, might prevent inflammation and subsequent alveolar bone resorption in a mouse model of periodontal disease.MethodsPeriodontitis was induced in mice by oral inoculations with P. gingivalis for a total of eight times over 24 days. The infected mice were treated with either GB88 or vehicle for the duration of the trial. Following euthanasia on day 56, serum was collected and used for the detection of mast cell tryptase. The right maxillae were defleshed and stained with methylene blue to measure the exposed cementum in molar teeth. The left maxillae were prepared for cryosections followed by staining for tartrate‐resistant acid phosphatase to identify osteoclasts or with toluidine blue to identify mast cells. Reverse transcription quantitative PCR (RT‐qPCR) was used to quantify the expression of inflammatory cytokines in the gingival tissue. Supernatants of T‐lymphocyte cultures isolated from the regional lymph nodes were assayed using a cytometric bead array to measure the Th1/Th2/Th17 cytokine levels.ResultsMeasurement of the exposed cementum showed that GB88 reduced P. gingivalis‐induced alveolar bone loss by up to 69%. GB88 also prevented the increase in osteoclast numbers observed in the infected mice. Serum tryptase levels were significantly elevated in both the infected groups, and not altered by treatment. RT‐qPCR showed that GB88 prevented the upregulation of Il1b, Il6, Ifng and Cd11b. In T‐lymphocyte supernatants, only IFNγ and IL‐17A levels were increased in response to infection, but this was prevented by GB88 treatment.ConclusionsGB88 significantly reduced osteoclastic alveolar bone loss in mice infected with P. gingivalis, seemingly by preventing the upregulation of several inflammatory cytokines. PAR2 antagonism may be an effective treatment strategy for periodontal disease.